drugset / Trial / NCT00228527

Esomeprazole for Treatment of GERD in Pediatric Patients

NCT00228527

Phase 4 Completed 100 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

To look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease (GERD) and diagnosed by endoscopy. To verify the healing of the esophageal inflammation if the endoscopy reveals cuts in the lining of the food pipe. To collect information that will describe the psychological, social, and economic effects on the primary caregiver of raising children ages 1 to 5 years old with GERD.

Timeline

Start
2004-10
Primary completion
Completion
2005-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 5 mg
Subject Esomeprazole Small molecule 10 mg
Subject Esomeprazole Small molecule 20 mg